论文部分内容阅读
目的观察缬沙坦对肝纤维化患者肝纤维化程度的影响。方法 60例肝纤维化患者随机分为对照组(28例)和治疗组(32例)。对照组予以恩替卡韦片,每次0.5 mg,每日1次,复方鳖甲软肝片,每次2 g,每天3次。治疗组在对照组基础上加用缬沙坦胶囊,每次80 mg,每日1次。2组疗程均为6个月。于治疗前后检测肝功能丙氨酸氨基转移酶(ALT)、谷草转氨酶(SGOT)、总胆红素(TBIL)和肝纤维化指标透明质酸(HA)、层粘联蛋白(LN)、Ш型前胶原(PC-Ш)、Ⅳ型胶原(Ⅳ-C)及Fibroscan值变化。结果治疗后,治疗组的血清肝功能指标ALT、SGOT、TBIL及肝纤维化指标LN、HA、PC-Ш、Ⅳ-C和Fibroscan值均较治疗前降低(P<0.05),且明显低于对照组(P<0.05)。结论缬沙坦胶囊联合恩替卡韦片和复方鳖甲软肝片治疗肝纤维化疗效确切。
Objective To observe the effect of valsartan on the degree of liver fibrosis in patients with liver fibrosis. Methods Sixty patients with liver fibrosis were randomly divided into control group (28 cases) and treatment group (32 cases). The control group was entecavir tablets, each 0.5 mg, 1 day, Fufang Biejia Ruangan tablet, 2 g each time, 3 times a day. The treatment group was added valsartan capsules on the basis of the control group, 80 mg each time, once daily. Two groups of treatment were 6 months. The levels of liver function alanine aminotransferase (ALT), aspartate aminotransferase (SGOT), total bilirubin (TBIL) and indicators of liver fibrosis (HA), laminin Type procollagen (PC-Ш), type Ⅳ collagen (Ⅳ-C) and Fibroscan value changes. Results After treatment, the serum ALT, SGOT, TBIL and liver fibrosis indexes LN, HA, PC-Ш, IV-C and Fibroscan in treatment group were lower than those before treatment (P <0.05) Control group (P <0.05). Conclusion Valsartan capsules combined with entecavir and Fufang Biejia Ruangan Tablet in the treatment of hepatic fibrosis have definite effect.